Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13) — A novel approach for the treatment of inflammatory bowel disease

2006 ◽  
Vol 6 (13-14) ◽  
pp. 1925-1934 ◽  
Author(s):  
Ute Bank ◽  
Anke Heimburg ◽  
Martin Helmuth ◽  
Sofia Stefin ◽  
Uwe Lendeckel ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Aminopeptidase N ◽  
Novel Approach ◽  
Inflammatory Bowel

scholarly journals Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults

Diabetes Care ◽  
2019 ◽  
Vol 42 (11) ◽  
pp. 2065-2074
Author(s):  
Tiansheng Wang ◽  
Jeff Y. Yang ◽  
John B. Buse ◽  
Virginia Pate ◽  
Huilin Tang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Real World ◽  
Bowel Disease ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Real World Evidence ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Inflammatory Bowel

scholarly journals Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease

2021 ◽  
Vol 12 (3) ◽  
pp. e00320
Author(s):  
Pedro Pinto-Lopes ◽  
Francisco Melo ◽  
Joana Afonso ◽  
Rui Pinto-Lopes ◽  
Cátia Rocha ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document